Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial

MLA

Giampaolo Bianchini, et al. “Abstract GS3-07: Circulating Tumor DNA (CtDNA) Dynamics in Patients with Hormone Receptor Positive (HR+)/HER2 Negative (HER2-) Advanced Breast Cancer (ABC) Treated in First Line with Ribociclib (R) and Letrozole (L) in the BioItaLEE Trial.” Cancer Research, vol. 82, Feb. 2022, pp. GS3-07. EBSCOhost, https://doi.org/10.1158/1538-7445.sabcs21-gs3-07.

APA

Giampaolo Bianchini, Luca Malorni, Grazia Arpino, Alberto Zambelli, Fabio Puglisi, Lucia Del Mastro, Marco Colleoni, Filippo Montemurro, Giulia Bianchi, Ida Paris, Giacomo Allegrini, Marina Elena Cazzaniga, Michele Orditura, Claudio Zamagni, Stefano Tamberi, Daniela Castelletti, Matteo Benelli, Maurizio Callari, Angela Santoro, & Michelino De Laurentiis. (2022). Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial. Cancer Research, 82, GS3-07. https://doi.org/10.1158/1538-7445.sabcs21-gs3-07

Chicago

Giampaolo Bianchini, Luca Malorni, Grazia Arpino, Alberto Zambelli, Fabio Puglisi, Lucia Del Mastro, Marco Colleoni, et al. 2022. “Abstract GS3-07: Circulating Tumor DNA (CtDNA) Dynamics in Patients with Hormone Receptor Positive (HR+)/HER2 Negative (HER2-) Advanced Breast Cancer (ABC) Treated in First Line with Ribociclib (R) and Letrozole (L) in the BioItaLEE Trial.” Cancer Research 82 (February): GS3-07. doi:10.1158/1538-7445.sabcs21-gs3-07.